Nasdaq:US$17.69 (-2.18) | HKEX:HK$29.50 (-2.25) | AIM:£2.98 (-0.36)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-11-05

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans